Pos1220 pregnant and Postpartum Women With Autoimmune Rheumatic Diseases and Covid-19: A Case Series

Abstract

Background:Pregnant women represent a high-risk population during the COVID-19 pandemic. The main cause of maternal deaths in Mexico during 2020 was COVID-19 with 191 (21.2%) deaths registered until December 2020. The age group most affected was 30 to 34 years. Women during their third trimester and during puerperium were the most affected. Information regarding pregnant and postpartum women with autoimmune rheumatic diseases remains scarce.Objectives:The aim of this study was to describe a COVID-19 case series from a clinic of pregnancy and rheumatic diseases.Methods:We conducted a descriptive, retrospective study in patients from the clinic of pregnancy and rheumatic diseases of the University Hospital “Dr. Jose Eleuterio Gonzalez” in Monterrey, Mexico. Pregnant patients with RD and documented COVID-19 between March and November 2020 were included. Demographic and clinical features were obtained. Results are shown in descriptive statistics.Results:From the 18 women with autoimmune rheumatic disease in follow-up during this period, 2 (11.1%) pregnant women, 2 (11.1%) postpartum women, and 1(5.5%) post-miscarriage woman developed COVID-19. The mean age was 28 ± 6.3 years, 3 (60%) had systemic lupus erythematosus, 1 (20%) had rheumatoid arthritis, and 1 (20%) had the antiphospholipid syndrome. Clinical features and treatments are shown in Graphic 1 and Table 1. The most frequent symptoms were fever (80%), cough (60%) and anosmia (60%). Four (80%) had mild symptoms, and 1 (20%) had severe symptoms requiring intensive care unit admission and mechanical ventilation. Three (60%) referred history of contact with a person who had COVID-19. All the patients were using hydroxychloroquine and prednisone. No patient in our study died.Conclusion:From our population, a total of 27.8% presented COVID-19. Most of our patients had a mild course of SARS-CoV-2 infection consistent with data from the general population. Additionally, none of our patients had risk factors such as hypertension, diabetes, chronic kidney disease or lung disease. Nonetheless, pregnant women remain a vulnerable population. Prevention measures must continue worldwide to avoid additional COVID-19 morbidity and mortality.References:[1]Gob.mx. 2021. INFORME SEMANAL DE NOTIFICACIÓN INMEDIATA DE MUERTE MATERNA. [online] Available at: <https://www.gob.mx/cms/uploads/attachment/file/601780/MM_2020_SE51.pdf> [Accessed 10 January 2021].[2]Arentz M, Yim E, Klaff L, et al. Characteristics and Outcomes of 21 Critically Ill Patients With COVID-19 in Washington State. JAMA. 2020;323(16):1612–1614. doi:10.1001/jama.2020.4326Graphic 1.Diagnosis, severity disease and clinical symptoms of pregnant rheumatic disease patients with COVID-19Table 1.Features, preventive measures, and treatments of pregnant rheumatic disease patients with COVID-19N=5Age, years, mean (SD)28 (6.36)Obesity, n (%)2 (40)Current occupation, n (%) Employee3 (60) Student1 (20) Housewife1 (20) Positive PCR test, n (%)5 (100)Prevention measures, n (%) Social Distancing2 (40) Quarantine3 (60) Contact with a person who had COVID-193 (60)Treatments used before disease, n (%) Prednisone5 (100) Hydroxychloroquine5 (100) Sulfasalazine2 (40) Azathioprine1 (20) Methotrexate*1 (20)Rheumatic treatment during disease, n (%) Continued3 (60) Suspended2 (40)PCR: polymerase chain reaction, *Methotrexate was used during conception and suspended immediately after the pregnancy detection.Disclosure of Interests:None declared